PDB43 SHOULD WE LOOK FOR A NEWAPPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?  by Sieradzki, J et al.
A168 Abstracts
members to follow up with their physicians; patient reminder
postcards; educational materials and newsletters; Diabetic
Control Network—a 12-month patient self educated program;
vision provider contract requirement included performance guar-
antees to improve eye exam rates; mailings to providers a list of
their diabetic patients who had not received the necessary ser-
vices; provider and patient gift certiﬁcate incentive programs;
providers on site education, and updated ADA diabetes stan-
dards of care. Results of baseline measurement and 12-month
post intervention re-measurement were compared. RESULTS: A
signiﬁcant improvement in all selected quality indicators were
found: HbA1c poorly controlled rate was 48.42%, a decreased
of 19.46% (p < 0.001) from baseline; eye exam rates was
48.66%, an increased of 10.70% (p < 0.05) from baseline; LDL-
C level <130mg/dL was 55.96%, an increased of 10.46% (p <
0.05) from baseline, LDL-C level <100mg/dL was 31.87%; and
nephropathy monitoring was 53.28%, an increased of 8.51% (p
< 0.05) from baseline. CONCLUSIONS: Results of this study
demonstrated substantial improvement in all selected diabetes
indicators. Although results of our interventions are encourag-
ing, expanded effort is still needed to further improve rates of
diabetic management among Medicaid members.
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The high prevalence of undiagnosed diabetes and the large pro-
portion of individuals with complications at diagnosis (50%
according to UKPDS 33) argue for screening for Type-2 diabetes.
The NHANES study conﬁrms the substantially higher risk of
death, lower survival, and lower life expectancy of diabetic
adults compared with non-diabetic adults. A UK Prospective
Diabetes Study shows that intensive blood-glucose control can
reduce risk of any diabetes-related death and any diabetes-
related endpoints. OBJECTIVE: The aim of the study was to
assess cost-effectiveness of active screening for DM and intensive
blood-glucose control in comparison with conventional treat-
ment in patients with DM II in the Polish population.
METHODS: The Markov model of DM progression to stimu-
late lifetime and related health care cost was constructed. Demo-
graphic characteristics of a stimulated cohort as well as cost of
health care were based on a CODIP study population. Costs
were analysed from a societal viewpoint and included only direct
medical costs. Costs of active searching for DM and the distrib-
ution of people on diagnostic pathways came from an epidemi-
ological Screen-Pol 2 study. The age-dependant risk of death and
transition probabilities between disease stages were obtained
from the NHANES study. The effectiveness of active blood-
glucose control was derived from the UKPDS 33. RESULTS: In
the long term (20 years), a strategy based on active blood-glucose
control could bring an additional 0.4 life years saved (LYS) per
patient. An additional LYS costs €457. If active blood-glucose
control is preceded by the active screening for DM, this strategy
could bring 0.71 LYS per patient. The cost-effectiveness ratio
amounts to €10,863/LYS. CONCLUSIONS: The most effective
strategy in DM management is based on an early detection
program and active blood-glucose control. The cost-effectiveness
ratio for active glucose control is extremely low.
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OBJECTIVE: Use of acetyl salicylic acid (ASA) for primary pre-
vention (PP) and secondary prevention (SP) of cardiovascular
disease (CVD) in adult diabetic patients is highly recommended.
This study was conducted in order to determine the use of ASA
and to assess the achievement of therapeutic targets in diabetic
patients. METHODS: This is a retrospective and observational
study. Sample consisted of patients >18 years with diabetes 
mellitus followed in four primary care centers. Measurements
included demographics, use of ASA and/or anticoagulant drugs,
co-morbidities, clinical parameters and proportion of patient at
therapeutic target (TT). Descriptive statistics, chi-square test and
logistic regression model were used for signiﬁcance. RESULTS:
A total of 4140 diabetic patients were analyzed, 79.1% 
(95% conﬁdence interval: 77.7%–80.5%) in PP and 20.9%
(18.2%–23.7%) in SP. Mean age was 64.1 (13.8) years, and
49.3% of patient were men (PP: 46.3; SP: 60.7; p = 0.000). ASA
were prescribed on a routine basis in 29.2% (27.8%–30.6%);
20.8% (19.4%–22.2%) in PP and 60.8% (57.6%–64.0%) in SP.
Proportion of patient at TT was 48.0% for hypertensives and
59.8% for hypercholesterolemics, being these the most frequent
antecedents observed in SP. Older patients [OR = 1.01
(1.00–1.02); p = 0.011], number of cardiovascular-risk factors
[OR = 1.14 (CI: 1.03–1.27); p = 0.013], LDL-c TT [OR = 1.42
(1.06–1.88); p = 0.017], and a poor metabolic control of gly-
cated hemoglobin [OR = 1.51 (1.22–1.89); p = 0.000] were
covariates associated to the use of ASS in PP. CONCLUSIONS:
Treatment with ASA is underused for PP in patients with dia-
betes mellitus in Primary Care. Achievement of TT should be
improved.
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OBJECTIVE: This study determined the predictors of antidia-
betes medication adherence and health care costs in adults with
Type-2 diabetes mellitus in the United States. METHODS: The
2000 Medical Expenditure Panel survey was used for the analy-
ses. The population for analyses was identiﬁed using ICD-9 CM
codes for Type-2 diabetes. The predictor variables were demo-
graphics variables, self-reported health status (EuroQol score),
and health services utilization variables. The dependent variables
in this analysis were diabetes medication possession (number of
diabetes medication reﬁlls) and annual health care costs. Multi-
variate weighted analysis was performed to identify signiﬁcant
predictors of medication utilization and health care costs.
RESULTS: There were 11.7 million patients with reported Type-
2 diabetes in the United States in 2000, based on survey extrap-
olation. On an average, there were ten diabetes drug reﬁlls
reported by patients. The average annual health care costs for
these patients were $7466, while the mean EuroQol summary
score was 48%. Increase in the health status summary score
(EuroQol) by 10% was associated with a slight (1%) decrease
in diabetes drug reﬁlls (p < 0.05). An additional diabetes related
emergency visit or an inpatient visit was associated with a nearly
50% increase compared to the average diabetes medication uti-
